Document:

<PAGE>
                                                                   EXHIBIT 10.19

October 19, 1999
Mr. Glen Sato
1470 Kings Lane
Palo Alto, CA  94303

Dear Glen:

Exelixis Pharmaceuticals, Inc. is pleased to offer you the position of Chief
Financial Officer and Vice President of Legal Affairs on the terms described
below.

As Chief Financial Officer and VP of Legal Affairs you will work in South San
Francisco, California and report to the President and Chief Executive Officer of
Exelixis.  You will perform the duties customarily associated with the position
of CFO and will have additional responsibility for legal affairs.  You will also
have responsibility for administration, including facilities and Human
Resources, and such other duties as may be assigned to you by the Company's
President and Chief Executive Officer.  Provided you have no objection, your
start date will be November 3, 1999.

Your initial base salary will be $210,000 per year less standard deductions and
withholdings, paid semi-monthly.  In addition, you will be eligible for a target
bonus of 30% of base salary, at the discretion of the Board of Directors, based
on annualized objectives to be established by the CEO and Board for your
position.  As with all executives, receipt of this year-end bonus will be
subject to the achievement of our annual financial plan and individual
management objectives.

Upon approval by the Board on or about the date your employment commences with
Exelixis, you will receive an incentive stock option grant, under the terms of
the Company's Equity Incentive Plan, in the total amount of 325,000 shares of
Exelixis common stock at an exercise price of $0.30 per share.  This grant will
vest over four years in equal shares on the last day of each calendar quarter in
accordance with the Company's standard vesting policy.  Other terms of the
option will be consistent with the Company's Equity Incentive Plan and with the
terms set forth in the Company's standard form of stock option grant.  From time
to time, the Board reviews the outstanding option grants for senior Company
executives and may issue additional options in the future, at its discretion.

In addition to your salary and incentive compensation, you will be eligible for
the following Company benefits consistent with Company policy:  three weeks of
vacation per year, annual physical examination, life insurance, and medical and
dental coverage.  Dependent medical and dental coverage is also available, paid
in part by the Company and in part by you, in accordance with Exelixis policy.
If necessary, Exelixis will reimburse you for your medical and dental insurance
under the COBRA plan of your previous employer until you are eligible for our
coverage (90 days from your date of hire).  Details about these benefits are
provided in the Employee Manual Summary Plan Descriptions.  The Company reserves
the right to modify your compensation and benefits from time to time, as it
deems necessary.

The Company will reimburse you for reasonable documented business expenses
pursuant to Company policy.  Of course, you will be expected to abide by all of
the Company's policies and procedures.  As a further condition of your
employment, you agree to refrain from any

                                       1.
<PAGE>

unauthorized use or disclosure of the Company's proprietary or confidential
information or materials. You also agree to sign and comply with the Company's
Confidentiality Agreement (attached). By accepting this offer, you are
representing that you are not a party to any agreement with any third party or
prior employer that would conflict with or inhibit your performance of your
duties with Exelixis.

You may terminate your employment with Exelixis at any time and for any reason
whatsoever simply by notifying the Company.  Likewise, Exelixis may terminate
your employment at any time and for any reason whatsoever, with or without cause
or advance notice.  If you are terminated without cause, you will be entitled to
receive salary and benefits for a period of 6 months from the date of the
termination.  This at-will employment relationship cannot be changed except in
writing signed by a Company officer.

This letter, together with the Confidentiality Agreement, constitutes the
complete, final and exclusive embodiment of the entire agreement between you and
Exelixis with respect to the terms and conditions of your employment.  In
entering into this agreement, neither party is relying upon any promise or
representation, written or oral, other than those expressly contained herein,
and this agreement supersedes any other such promises, representations or
agreements.  It may not be amended or modified except in a written agreement
signed by you and a duly authorized Company officer.  As required by law, this
offer of employment is subject to proof of your right to work in the United
States.

To ensure rapid and economical resolution of any disputes that may arise under
this agreement, you and the Company agree that any and all disputes or
controversies of any nature whatsoever, regarding the interpretation,
performance, enforcement or breach of this Agreement will be resolved by
confidential, final and binding arbitration (rather than trial by jury or court
or resolution in some other forum) under the then-existing rules of Judicial
Arbitration and Mediation Services ("JAMS").

Sincerely,

/s/ George Scangos
------------------------------
George Scangos

                                       2.<PAGE>

                                                                   Exhibit 10.29
                                                                   -------------

                                          January 28, 2000

J.P. Morgan Securities Inc.
Bear, Stearns & Co. Inc.
U.S. Bancorp Piper Jaffray Inc.
As Representatives of the Underwriters
     named in Schedule I to the
  Underwriting Agreement referred to below
c/o J.P. Morgan Securities Inc.
  60 Wall Street
  New York, NY 10260

     Re:  Vicinity Corporation -- Public Offering

Ladies and Gentlemen:

     The undersigned understands that you, as Representatives of the several
Underwriters, propose to enter into an Underwriting Agreement (the "Underwriting
Agreement") with Vicinity Corporation, a California corporation (the "Company"),
providing for the public offering (the "Public Offering") by the several
Underwriters named in Schedule I to the Underwriting Agreement (the
"Underwriters"), of Common Stock, $.001 par value, of the Company (the
"Securities"). Capitalized terms used herein and not otherwise defined shall
have the meanings set forth in the Underwriting Agreement.

     In consideration of the Underwriters' agreement to purchase and make the
Public Offering of the Securities, and for other good and valuable consideration
receipt of which is hereby acknowledged, the undersigned hereby agrees that,
without the prior written consent of J.P. Morgan Securities Inc. on behalf of
the Underwriters, the undersigned will not, during the period ending 270 days
after the date of the prospectus relating to the Public Offering (the
"Prospectus"), (1) offer, pledge, announce the intention to sell, sell, contract
to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock,
$.001 per share par value, of the Company (the "Common Stock") or any securities
convertible into or exercisable or exchangeable for Common Stock (including
without limitation, Common Stock which may be deemed to be beneficially owned by
the undersigned in accordance with the rules and regulations of the Securities
and Exchange Commission and

<PAGE>

securities which may be issued upon exercise of a stock option or warrant) or
(2) enter into any swap or other agreement that transfers, in whole or in part,
any of the economic consequences of ownership of the Common Stock, whether any
such transaction described in clause (1) or (2) above is to be settled by
delivery of Common Stock or such other securities, in cash or otherwise. In
addition, the undersigned agrees that, without the prior written consent of J.P.
Morgan Securities Inc. on behalf of the Underwriters, it will not, during the
period ending 270 days after the date of the Prospectus, make any demand for or
exercise any right with respect to, the registration of any shares of Common
Stock or any security convertible into or exercisable or exchangeable for Common
Stock.

     In furtherance of the foregoing, the Company, and any duly appointed
transfer agent for the registration or transfer of the securities described
herein, are hereby authorized to decline to make any transfer of securities if
such transfer would constitute a violation or breach of this Letter Agreement.

     The undersigned hereby represents and warrants that the undersigned has
full power and authority to enter into this Letter Agreement. All authority
herein conferred or agreed to be conferred and any obligations of the
undersigned shall be binding upon the successors, assigns, heirs or personal
representatives of the undersigned.

     The undersigned understands that, if the Underwriting Agreement does not
become effective, or if the Underwriting Agreement (other than the provisions
thereof which survive termination) shall terminate or be terminated prior to
payment for and delivery of the Common Stock to be sold thereunder, the
undersigned shall be released from all obligations under this Letter Agreement.

     The undersigned understands that the Underwriters are entering into the
Underwriting Agreement and proceeding with the Public Offering in reliance upon
this Letter Agreement.

     This lock-up agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to the conflict of laws
principles thereof.

                               Very truly yours,

                               Hikari Tsushin, Inc.

                               By:_____________________________________
                                 Name:
                                 Title:

                                       2

<PAGE>

Accepted as of the date first set forth above:

J.P. Morgan Securities Inc.
Bear, Stearns & Co. Inc.
U.S. Bancorp Piper Jaffray Inc.
Acting severally on behalf of themselves
          and the several Underwriters
     named in Schedule I to the
     Underwriting Agreement

By:  J.P. MORGAN SECURITIES INC.

By: ___________________________________________________________
    Name:
    Title:

By: BEAR, STEARNS & CO. INC.

By: ___________________________________________________________
    Name:
    Title:

By: U.S. BANCORP PIPER JAFFRAY
    INC.

By: ___________________________________________________________
    Name:
    Title:

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]